Adcetris approved by the FDA

Submitted by Ross Bonander Tue 08/23/2011

Share on Tumblr

Call (877) 399-6937 or click here to learn more about Cancer Treatment options.

Adcetris, formerly known as SGN-35 and one of the more anticipated anti-cancer drugs in recent memory, has received accelerated market approval from the FDA.

Adcetris has been approved for two indications: for patients with Hodgkin's lymphoma who have already received an autologous stem cell transplantation (or for patients who have endured at least two chemotherapy regimens and are not transplant candidates), and for patients with anaplastic large T-cell lymphoma (ALCL) who failed induction therapy. It is the first treatment approved for Hodgkin's since 1977 and the first-ever treatment approved for ALCL.

Developed by Seattle Genetics, Adcetris is a first-in-class therapy known as an antibody drug conjugate; it uses a monoclonal antibody to seek out cells expressing CD30 on their surfaces and delivers an cytotoxic payload, killing the cell.

Resources

Click HERE for more information on Adcetris.

Click HERE for the FDA announcement.

Call (877) 399-6937 or click here to learn more about Cancer Treatment options.

Support Groups

SupportGroups.com

For individuals, friends and families who are looking to connect during life's challenging times. Share personal experiences, evaluate information and get support during times of need, illness, treatment or recovery.

Cancer Support Groups

Find a Treatment Facility Near You

Click on a state below to find Lymphoma treatment options that could be right for you.

Select a State Below

The information provided on the Lymphoma Information Network is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational and educational purposes. The publication of this information does not constitute the practice of medicine, and this information does not replace the advice of your physician or other health care provider. Neither the owners or employees of LymphomaInfo.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.